Compare TRT & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRT | VTVT |
|---|---|---|
| Founded | 1958 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 109.1M | 129.7M |
| IPO Year | 1995 | 2015 |
| Metric | TRT | VTVT |
|---|---|---|
| Price | $4.92 | $26.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $56.00 |
| AVG Volume (30 Days) | ★ 423.6K | 28.6K |
| Earning Date | 09-24-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $32,462,000.00 | N/A |
| Revenue This Year | $26.89 | N/A |
| Revenue Next Year | $25.30 | N/A |
| P/E Ratio | $365.50 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.63 | $19.80 |
| 52 Week High | $21.38 | $44.00 |
| Indicator | TRT | VTVT |
|---|---|---|
| Relative Strength Index (RSI) | 22.48 | 31.34 |
| Support Level | $4.42 | N/A |
| Resistance Level | $6.54 | $34.65 |
| Average True Range (ATR) | 0.32 | 1.35 |
| MACD | -0.05 | -0.35 |
| Stochastic Oscillator | 4.93 | 0.18 |
Trio-Tech International is a provider of reliability test equipment and services to the semiconductor and other industries. Its customers are from automotive electronics, industrial electronics, computing and data storage, consumer electronics, and communication markets. The company operated its business in two segments: Semiconductor Back-end Solutions and Industrial Electronics. Geographically, the company operates in the United States (U.S), Singapore, Malaysia, Thailand and China.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.